We are live on ! Find out more

MiMedx Group

MDXG

Market cap $657M

4.51 USD

+0.09

2.04%

At close Updated Aug 27, 4:00 PM EDT

Pre-market

After hours

4.55

+0.04

0.89%

1 day

2.04%

5 days

4.88%

1 month

5.87%

3 months

24.93%

6 months

-7.77%

Year to date

-30.4%

1 year

-37.1%

5 years

-68.01%

10 years

-36.48%

About: MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Employees: 808

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 16.7%

Neutral 83.3%

Negative 0%

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sanara MedTech Inc. (NasdaqCM: SMTI) to MiMedx Group, Inc. (NasdaqCM: MDXG). Under the terms of the proposed transaction, shareholders of Sanara will receive $33.00 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara that they own. KSF is seeking to determine whether this c.

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

MiMedx Group Q2 Earnings Call Highlights

MiMedx Group NASDAQ: MDXG said it has agreed to acquire Sanara MedTech in a transaction valued at $35 per Sanara share, a deal the company expects to close by the end of 2026. The announcement accompanied MiMedx's second-quarter results, which showed sequential improvement in its wound-care business and continued growth in surgical sales.

MiMedx Group Q2 Earnings Call Highlights

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

Reports Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standalone Basis Announces Plans to Acquire Sanara MedTech Management to Host Conference Call Today, July 29, 2026, at 4:30 PM ET MARIETTA, Ga., July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2026.

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

MIMEDX to Acquire Sanara MedTech

Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX's Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX's Second Quarter 2026 Operating and Financial Results Today at 4:30pm EDT MARIETTA, Ga. and FORT WORTH, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Sanara MedTech Inc. (“Sanara,” “Sanara MedTech”) (Nasdaq: SMTI) today announced that they have entered into a definitive merger agreement under which MIMEDX will acquire all of the outstanding shares of Sanara in a cash and stock transaction valued at $35 per Sanara share with a total enterprise value of approximately $350 million.

MIMEDX to Acquire Sanara MedTech

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, July 29, 2026.

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the Craig-Hallum 23 rd Annual Institutional Investor Conference on Thursday, May 28, 2026 in Minneapolis, MN. Investors interested in meeting with senior management may contact their Craig-Hallum representative.

MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG

See News Rankings

Price charts implemented using Lightweight Charts™